title: Lysis onset time as diagnostic rotational thromboelastometry parameter for fast detection of hyperfibrinolysis.
abstract: BACKGROUND
  Rotational thromboelastometry is increasingly used to detect hyperfibrinolysis, which is a predictor of unfavorable outcome in patients with coagulation disturbances. In an in vitro study, the authors investigated which thromboelastometric hemostatic parameters could be valuable for fast diagnosis of the severity of hyperfibrinolysis and confirmed their findings in a patient population with hyperfibrinolysis.
  
  
  METHODS
  Thromboelastometry was performed after adding increasing concentrations of tissue plasminogen activator (0 to 400 ng/ml) to citrated blood samples of 15 healthy volunteers. Lysis parameters included the clotting time, maximum clot firmness, maximum lysis, and lysis onset time (LOT). The relation of tissue plasminogen activator with the LOT was further investigated in a patient population with out-of-hospital cardiac arrest and hyperfibrinolysis.
  
  
  RESULTS
  The LOT showed a dose-dependent association with increasing tissue plasminogen activator concentrations. Late, intermediate, or fulminant hyperfibrinolysis was associated with an average LOT (mean ± SD) of 42.7 ± 13.8, 23.2 ± 8.2, and 17.5 ± 4.6 min in the in vitro study and estimated 42.2 ± 8.3, 29.1 ± 1.2, and 14.6 ± 7.7 min in patients, respectively. The authors found a moderately negative correlation between patient plasma tissue plasminogen activator levels and the LOT (r = -0.67; P = 0.01).
  
  
  CONCLUSIONS
  This study shows that the LOT may be used for fast detection of severe hyperfibrinolysis, with a better resolution than the maximum lysis, and should be further evaluated for optimization of therapeutic strategies in patients with severe clot breakdown.
authors.affiliation: From the Department of Anesthesiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (S.E.D., V.A.V., A.D., M.d.J., C.E.v.d.B., P.S., C.B.); and Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands (P.M.v.d.V.).
authors.forename: Simone Esther
authors.initials: SE
authors.lastname: Dekker
authors.forename: Victor Alexander
authors.initials: VA
authors.lastname: Viersen
authors.forename: Anne
authors.initials: A
authors.lastname: Duvekot
authors.forename: Merijn
authors.initials: M
authors.lastname: de Jong
authors.forename: Charissa Esmé
authors.initials: CE
authors.lastname: van den Brom
authors.forename: Peter M
authors.initials: PM
authors.lastname: van de Ven
authors.forename: Patrick
authors.initials: P
authors.lastname: Schober
authors.forename: Christa
authors.initials: C
authors.lastname: Boer
mesh_terms: D000328:Adult; D000368:Aged; D001776:Blood Circulation Time / Q000187:drug effects; D016887:Cardiopulmonary Resuscitation; D004305:Dose-Response Relationship, Drug; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology*; D006323:Heart Arrest / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D011446:Prospective Studies; D012016:Reference Values; D013916:Thrombelastography / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000494:pharmacology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010959:Tissue Plasminogen Activator